Jasper Therapeutics, Inc. SEC filings JSPR
Jasper Therapeutics, Inc. has 483 filings in SEC EDGAR's recent list, going back to Sep 13, 2019. Its latest annual report, Form ARS, was filed on Jun 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (change to shareholder rights, bylaw or fiscal year change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Oct 14, 2026 | — |
| 424B5 | Prospectus supplement | Sep 19, 2025 | — |
| 424B5 | Prospectus supplement | Sep 18, 2025 | — |
| 424B5 | Prospectus supplement | Mar 26, 2025 | — |
| S-3 | Shelf registration | Mar 19, 2025 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 7, 2024 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 7, 2024 | — |
| S-8 POS | Post effective amendment no. 1 to form s-8 | Jun 7, 2024 | — |
| S-8 | Employee stock plan registration | Jun 7, 2024 | — |
| S-8 | Employee stock plan registration | Mar 5, 2024 | — |
| 424B5 | Prospectus supplement | Feb 7, 2024 | — |
| S-8 | Employee stock plan registration | Aug 11, 2023 | — |
| 424B5 | Prospectus supplement | May 5, 2023 | — |
| S-3 | Shelf registration | Apr 28, 2023 | — |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| 424B5 | Prospectus supplement | Jan 25, 2023 | — |
| 424B5 | Prospectus supplement | Jan 24, 2023 | — |
| 424B5 | Prospectus supplement | Nov 10, 2022 | — |
| 424B3 | Prospectus | Oct 18, 2022 | — |
| POS AM | Post-effective amendment no. 2 to form s-1 | Oct 7, 2022 | — |
| S-3 | Shelf registration | Oct 7, 2022 | — |
| 424B3 | Prospectus | Aug 12, 2022 | — |
| 424B3 | Prospectus | May 12, 2022 | — |
| 424B3 | Prospectus | Apr 1, 2022 | — |
| POS AM | Post effective registration statement | Mar 24, 2022 | — |
| S-8 | Employee stock plan registration | Mar 22, 2022 | — |
| S-8 | Employee stock plan registration | Mar 18, 2022 | — |
| 424B3 | Prospectus | Nov 12, 2021 | — |
| 424B3 | Prospectus | Oct 29, 2021 | — |
| 424B3 | Prospectus | Oct 26, 2021 | — |
| S-1 | Registration statement | Oct 18, 2021 | — |
| 424B3 | Prospectus | Aug 26, 2021 | — |
| S-4/A | Registration statement | Aug 25, 2021 | — |
| S-4/A | Registration statement | Aug 20, 2021 | — |
| S-4/A | Registration statement | Aug 9, 2021 | — |
| S-4/A | Registration statement | Jul 19, 2021 | — |
| S-4 | Registration for a merger or exchange | Jun 8, 2021 | — |
| 424B4 | Prospectus | Nov 21, 2019 | — |
| S-1/A | Amended registration statement | Nov 14, 2019 | — |
| S-1/A | Amended registration statement | Nov 8, 2019 | — |
| S-1/A | Amended registration statement | Nov 6, 2019 | — |
| S-1 | Registration statement | Oct 25, 2019 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- JSPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1788028
- Former names
- Amplitude Healthcare Acquisition Corp (until Sep 29, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.